AllPennyStocks.com ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?

The selloff followed topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, or SLE, a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissues.

Other Penny Stock Movers

From Bitcoin to Big League Sports
Drill Hits 30% Hydrogen as Gas Reaches Surface
The First Ounces Out of a New Mine Are Almost Always Spoken For
Most Popular
{{ index + 1 }}


Back to Top